![]() | |
Identifiers | |
---|---|
PubChem CID | |
ChemSpider | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C18H24N4O5 |
Molar mass | 376.413 g·mol−1 |
3D model ( JSmol) | |
| |
|
Ro 44-3888 is a non-peptidic, selective and reversible glycoprotein IIb/IIIa inhibitor. It is the active metabolite of sibrafiban. [1] It was being investigated as a treatment for heart conditions, including myocardial infarctions. The development of Ro 44-3888 and sibrafiban was discontinued in 1999 following unfavorable Phase III efficacy data.
![]() | |
Identifiers | |
---|---|
PubChem CID | |
ChemSpider | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C18H24N4O5 |
Molar mass | 376.413 g·mol−1 |
3D model ( JSmol) | |
| |
|
Ro 44-3888 is a non-peptidic, selective and reversible glycoprotein IIb/IIIa inhibitor. It is the active metabolite of sibrafiban. [1] It was being investigated as a treatment for heart conditions, including myocardial infarctions. The development of Ro 44-3888 and sibrafiban was discontinued in 1999 following unfavorable Phase III efficacy data.